Quantitative TP53 circulating tumor DNA predicts tumor response and survival outcomes in esophageal squamous cell carcinoma

Figure 5 Prognostic impact of TP53 circulating tumor DNA in esophageal squamous cell carcinoma patients. A: Disease-free survival according to postoperative TP53 circulating tumor DNA (ctDNA) status (positive vs negative); B: Overall survival based on postoperative TP53 ctDNA detection; C: Disease-free survival according to preoperative TP53 ctDNA variant allele frequency (≤ 0.32% vs > 0.32%); D: Overall survival according to preoperative TP53 ctDNA variant allele frequency (≤ 0.32% vs > 0.32%). All comparisons were performed using log-rank tests. VAF: Variant allele frequency; ctDNA: Circulating tumor DNA; CI: Confidence interval.